Unlike low-grade endometrial carcinomas, which often respond well to surgery and hormone therapy, PDEECs, especially those with TP53 mutations, tend to resist conventional therapies and require aggressive treatment approaches [36]. This evidence concerns the gene TP53 and endometrial carcinoma.